文献速递乳腺癌

帕博利珠单抗对比化疗对转移性三阴性乳腺癌患者健康相关生活质量的影响:3期随机KEYNOTE-119研究结果

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
PubMed 文献 · Eur J Cancer · 2023-10-21

KEYNOTE-119研究纳入既往治疗的转移性三阴性乳腺癌患者,随机接受帕博利珠单抗或化疗。预设生活质量分析显示,在肿瘤PD-L1 CPS≥10患者中,帕博利珠单抗组第6周QLQ-C30总体健康状况/生活质量及多个功能、症状领域较基线变化方向优于化疗,至恶化时间方向更长,其他终点差异极小。

要点

  • 在PD-L1 CPS≥10患者中,帕博利珠单抗组第6周QLQ-C30 GHS/QoL较基线变化的方向优于化疗。
  • 帕博利珠单抗组QLQ-C30 GHS/QoL至恶化中位时间方向长于化疗(4.3 vs 1.7个月)。
  • 其他健康相关生活质量终点的组间治疗差异极小。

核心结论

  • 健康相关生活质量结果与临床结局一致,且似乎由肿瘤PD-L1 CPS≥10患者的结果驱动。

研究设计与样本

  • KEYNOTE-119为3期随机研究(ClinicalTrials.gov,NCT02555657),患者按1:1随机接受帕博利珠单抗200 mg每3周静脉给药最多35个周期或由研究者按当地/国家指南选择的治疗。
  • 预设探索性终点为健康相关生活质量(EORTC QLQ-C30、QLQ-BR23)较基线变化及EQ-5D-3L效用特征,至恶化时间定义为从治疗开始至首次出现较基线≥10分恶化的时间。
  • 健康相关生活质量分析纳入187例肿瘤PD-L1联合阳性评分(CPS)≥10的患者。

主要发现

  • 第6周(主要分析时间点)时,帕博利珠单抗组对比化疗组QLQ-C30 GHS/QoL最小二乘均值组间差异为4.21(95%CI,-1.38至9.80)。
  • 第6周时,QLQ-C30功能量表(躯体、角色、认知、社会)、QLQ-C30症状量表/条目(疲乏、恶心/呕吐、呼吸困难、食欲丧失)及QLQ-BR23症状量表/条目(全身治疗副作用、因脱发烦恼)较基线变化方向均优于化疗。
  • QLQ-C30 GHS/QoL至恶化中位时间帕博利珠单抗组对比化疗组为4.3个月 vs 1.7个月,QLQ-C30恶心/呕吐为7.7个月 vs 4.8个月,QLQ-BR23全身治疗副作用为6.1个月 vs 3.4个月,方向均更长。
  • 其他健康相关生活质量终点的组间治疗差异极小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In KEYNOTE-119 (ClinicalTrials.gov, NCT02555657), overall survival (primary end-point) was similar between pembrolizumab and chemotherapy in patients with previously treated metastatic triple-negative breast cancer (TNBC), although the pembrolizumab treatment effect increased with tumour PD-L1 expression. We report results of prespecified health-related quality of life (HRQoL) analyses from KEYNOTE-119. METHODS: Eligible patients were randomised 1:1 to pembrolizumab 200 mg Q3W intravenously for up to 35 cycles or treatment of physician's choice per local/country guidelines. Prespecified exploratory end-points were the change from baseline in HRQoL (EORTC QLQ-C30, QLQ-BR23) and to characterise utilities (EQ-5D-3L). Time to deterioration (TTD) was the time from start of treatment to first onset of a ≥10-point worsening from baseline. RESULTS: HRQoL analyses included 187 patients with tumour PD-L1 combined positive score (CPS) ≥10. Changes from baseline at 6 weeks (primary analysis time point) were directionally better with pembrolizumab versus chemotherapy for QLQ-C30 GHS/QoL (between-group difference in least-squares mean scores of 4.21 [95% CI, -1.38 to 9.80]), QLQ-C30 functional scales (physical, role, cognitive, social), QLQ-C30 symptom scales/items (fatigue, nausea/vomiting, dyspnoea, appetite loss), and QLQ-BR23 symptom scales/items (systemic therapy side-effects, upset by hair loss). Median TTD was directionally longer for pembrolizumab versus chemotherapy for QLQ-C30 QHS/QoL (4.3 versus 1.7 months), QLQ-C30 nausea/vomiting (7.7 versus 4.8 months), and QLQ-BR23 systemic therapy side-effects (6.1 versus 3.4 months). Minimal treatment differences were observed for other HRQoL end-points. CONCLUSIONS: HRQoL results were consistent with clinical outcomes and appeared to be driven by results for patients with tumour PD-L1 CPS ≥10.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schmid P, Lipatov O, Im SA, et al. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. Eur J Cancer. 2023. PMID: 37976633. doi:10.1016/j.ejca.2023.113393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。